Insulin resistance and androgen levels in eugonadic and hypogonadic women with prolactinoma

Basit Öğe Kaydı
dc.contributor.authorDogan, Bercem A.
dc.contributor.authorBerker, Dilek
dc.contributor.authorArduc, Ayse
dc.contributor.authorTuna, Mazhar M.
dc.contributor.authorNasiroglu, Narin I.
dc.contributor.authorKarakilic, Ersen
dc.contributor.authorBasaran, Mehtap N.
dc.date.accessioned2024-04-24T17:37:33Z
dc.date.available2024-04-24T17:37:33Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractBACKGROUND: Hyperprolactinemia is the most common endocrinologic disorder in causing menstrual irregularities. Although the correlation between hyperprolactinemia and menstrual dysfunction is widely known, the etiology of menstrual cycle disorders is not profoundly understood in patients with prolactinoma. We aimed to investigate the correlation between prolactin levels and insulin resistance and hyperandrogenism in patients with prolactinoma. METHODS: Sixty-four patients with microprolactinoma and 33 healthy women were enrolled. Thirty-six of these patients with prolactinoma (group 1) had an estradiol (E2) level under 30 pg/mL, and 28 (group 2) had an E2 level greater than 30 pg/mL. Blood samples were drawn to measure the levels of the following hormones: Follicle stimulating hormone (FSH), luteinizing hormone (LH), E2, prolactin (PRL), total testosterone (TT), androstenedione (AS) and dehydroepiandrostenedione sulphate (DHEAS). Body Mass Index (BMI of >= 30 kg/m(2)) was excluded from the study. Insulin resistance (IR) was calculated by the HOMA-IR. RESULTS: BMI was higher in patients with prolactinoma than the control group (P=0.02, P=0.025, respectively). IR and glucose intolerance existence were higher in patients with prolactinoma (P=0.007, P=0.097, respectively) than the healthy women, but these differences did not exist between eugonadic and hypogonadic women with prolactinoma (P=0.020, P=0.032, respectively, Bonferroni correction). TT and AS were higher in eugonadic women with prolactinoma than the control group (P=0.004, P=0.003, Bonferroni correction, respectively). CONCLUSIONS: Our study revealed that the relationship between hyperprolactinemia and IR/glucose intolerance is irrespective of gonadal status in women with prolactinoma. Also, the study concluded that hyperandrogenism may be a cause of menstrual dysfunction in eugonadic women with prolactinoma.en_US
dc.identifier.endpage182en_US
dc.identifier.issn0391-1977
dc.identifier.issn1827-1634
dc.identifier.issue2en_US
dc.identifier.pmid25288097
dc.identifier.scopus2-s2.0-84992537803
dc.identifier.scopusqualityN/A
dc.identifier.startpage175en_US
dc.identifier.urihttps://hdl.handle.net/11468/21016
dc.identifier.volume41en_US
dc.identifier.wosWOS:000384945000004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherEdizioni Minerva Medicaen_US
dc.relation.ispartofMinerva Endocrinologica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProlactinomaen_US
dc.subjectAndrogensen_US
dc.subjectInsulin Resistanceen_US
dc.titleInsulin resistance and androgen levels in eugonadic and hypogonadic women with prolactinomaen_US
dc.titleInsulin resistance and androgen levels in eugonadic and hypogonadic women with prolactinoma
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu